Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:

- Vaccines, monoclonal antibodies, and supporting technologies for prevention and treatment of infectious diseases
 - Novel antigens and methods for antigen discovery and characterization
 - o New ways to administer vaccines, including mucosal routes
 - Nanoparticles, carrier proteins, and methods of conjugations proteins and polysaccharides
 - o mRNA vaccine technologies, including mRNA production and formulation methods
 - Novel vectors for delivering antigens
- Agents to enhance vaccine immune responses
 - o Adjuvants and immunomodulators
- Characterization and assays of immune responses and disease markers
 - Animal models, including of human diseases
 - Biological and immunological studies to characterize adjuvants and immunomodulators
 - o Biological markers for evaluating the efficacy of prophylactic or therapeutic interventions
 - o In vitro, ex vivo, and 3D models of human tissues, including the immune system
 - o B-cell immunology, and immunosenescence
 - o Imaging/bioimaging
 - Epidemiological studies relevant to the use of vaccines and immunotherapeutics
- Tools for improving vaccine and monoclonal antibody research, development and production
 - o Prokaryotic or eukaryotic cell lines for antigen production
 - o Upstream and downstream processes optimization technologies
 - Process automation
 - Preservatives and stabilizers
 - o Bioinformatics techniques for modeling, data handling and analysis
 - o Omics approaches related to biomarkers, safety, and correlates of immunity/protection
 - $\circ~$ AI, machine learning and machine vision
 - Nonionic detergents
 - Anti-counterfeiting technology
- Vaccines for disease areas that are of particular interest to us:
 - Nosocomial infections like *S. aureus and P. aeruginosa*, and others, including those that cover multiple pathogens
 - Viral infections: CMV, HSV, Influenza, Norovirus, Rotavirus, Rhinovirus, RSV, Bacterial infections: B. pertussis, Lyme disease, Meningococcal B, S. pneumoniae, Acne, Periodontal, E. coli (UTI)
 - o Pathogens exacerbating COPD or asthma